Aaron Ren, Ph.D., our CEO, is a biotechnology entrepreneur with both scientific and business background and brings nearly 20 years of biopharmaceutical experience spanning various functions in founding and growing companies.

Most recently, Dr. Ren was Co-Founder, Senior Vice President, Head of Business Development and Operations at the U.S. biotechnology company Viela Bio, which was acquired by Horizon Therapeutics for more than US$3 billion. At Viela, Dr. Ren had led a variety of functions, including business development, chemistry, manufacturing and controls (CMC), and supply chain, facility, legal, information technology, and quality. As a founding executive, he also led Viela’s efforts of financing to spin off from MedImmune of AstraZeneca and later helped grow Viela into a public traded commercial-stage company.

Before Viela, Dr. Ren was an executive at MedImmune, first with its Strategy and Partnering group, leading strategic projects and business development transactions, later as China lead managing its research and development initiatives for China. Before joining MedImmune, Dr. Ren was a management consultant at McKinsey and Company, advising biopharmaceutical companies on strategic, commercial, and organizational challenges. In addition, Dr. Ren held various roles with increasing responsibilities at SR One, Schering-Plough, and Abbott Labs, where he started his career as a senior clinical pharmacologist for Humira.

Dr. Ren received his B.Sc. in Cell Biology and Genetics from Peking University, his M.B.A. in Finance and Healthcare Management with honors from the Wharton School at the University of Pennsylvania, and his Ph.D. in Pharmaceutics from the University of Washington, during which he was an Eli Lilly Fellow.

ABOUT US

INNOVATION

MEDIA

CAREERS